Sglt 2 denied as not FDA-approved for this use by Aetna?

Aetna's specific coverage criteria for sglt2 are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna May Deny an SGLT2 Inhibitor as "Not FDA-Approved"

This denial occurs when Aetna concludes that the specific use being requested — the indication, patient population, or combination — is not within the FDA-approved labeling for the SGLT2 inhibitor prescribed. It may also arise from an administrative error in how the claim was coded, or from a mismatch between the ICD-10 diagnosis code submitted and the indication covered under the drug's label.

Because the SGLT2 class has expanded its FDA-approved indications over time — adding cardiovascular and renal indications beyond type 2 diabetes management — Aetna's review process may not have been updated to reflect more recent approvals. This makes the denial appealable on factual grounds.

## Federal Appeal Framework

• Internal appeal — file within the deadline shown on your denial notice. ERISA plans require Aetna to decide standard pre-service appeals within 30 days; urgent appeals within 72 hours. Request the specific rationale and the version of the FDA label Aetna relied upon.
• External review (ACA §2719 / ERISA §503) — if your internal appeal is denied, an independent external reviewer with relevant expertise will evaluate whether the denial was correct under current FDA approval status. The external-review window is generally approximately four months from the original denial. Expedited review is available for urgent situations.

## Documentation to Gather

• Current FDA-approved prescribing label — obtain the most current label for the exact SGLT2 inhibitor prescribed. Confirm the date of the most recent labeling update and identify the indication your prescriber is treating.
• Prescriber letter of medical necessity — the prescriber should quote the relevant approved indication language from the label, state the patient's diagnosis in matching terms, and confirm that the prescribed use is within that approved indication.
• Diagnosis documentation — chart notes, lab results, specialist records, and ICD-10 coding that clearly map the patient's condition to the label's approved indication. Ensure the coding submitted to Aetna aligns with the label language.
• Aetna's current clinical policy on SGLT2 inhibitors — identify the specific basis for the "not FDA-approved" determination and address it directly.
• Relevant guideline organization position — if applicable, include a citation to the guideline organization (e.g., ACC/AHA, ADA, KDIGO) that addresses the indication, to reinforce that the use is clinically mainstream.

## Criteria-Mapping Structure

| Question | Evidence | |---|---| | What indication is on the FDA label? | [Label language + approval date] | | What condition is being treated? | [Diagnosis + ICD-10 + chart date] | | Do they match? | [Prescriber's explicit confirmation] | | Was coding submitted correctly? | [Review claim codes vs. label indication] |

## Key Argument

A denial of "not FDA-approved" cannot stand when the prescribing label clearly covers the indication being treated. Present the label language and the patient's diagnosis side by side. If the denial appears to stem from outdated plan criteria that predate a more recent FDA label update, note the label's revision date explicitly and request that Aetna apply current approval status.